BIRC5 and central nervous system cancer: In addition, the clinical follow‐up data of glioma patients from TCGA database was analysed, and it was found that the 5‐year survival rate of patients with BIRC5 upregulation was significantly lower than that of patients with BIRC5 downregulation (Figure 4H).